Report Package: Hot targets for empowered antibody and cell therapy technologies

December 2016 | 202 pages | ID: R7CCE445BF2EN
La Merie Publishing

Abstracts

Report Package: Hot targets for empowered antibody and cell therapy technologies

This package contains three reports analyzing

• BCMA,
• CD123 and
• CD22

as versatile and hot targets for the successful application of empowered antibody and cell technologies, including:

• Fc-Engineered Antibodies;
• Radioimmunotherapy;
• Immunotoxins;
• Antibody-Drug Conjugates;
• T-Cell Redirecting Bispecific Antibodies;
• Chimeric Antigen Receptor (CAR) T-Cells.

The reports describe and discuss

• Target background, scientific rationale & expression profiles;
• Preclinical proof-of-concept;
• Clinical experience;
• Competitive landscape;
• Drug or cell therapy profiles;
• Company profiles.

Each of the three reports can be obtained individually, but the package of the three reports provides a 40% discount on the regular prices:

• B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities
• CD123: a paradigmatic target for immunotherapeutic treatment modalities
• CD22: a suitable antigen for targeted payload delivery by immunotherapeutics

Detailed report descriptions, tables of contents and samples from the reports can be found on the respective product page.

Contents

REPORT 1:

B-CELL MATURATION ANTIGEN (BCMA): HOT TARGET FOR EMERGING TREATMENT MODALITIES

Target Background
Target Antigen Expression Profile
Preclinical Proof-of-Concept
Clinical Indications & Treatment Options
Clinical Experience with BCMA-Targeted Treatment Modalities
Treatment Modalities & Competitive Landscape
  Drug & Cell Therapy Candidate Profiles
  CAR T-Cells
  Antibody-Drug Conjugate (ADC)
  T-Cell Redirecting Antibodies
Company Profiles
References

REPORT 2:

CD123: A PARADIGMATIC TARGET FOR IMMUNOTHERAPEUTIC TREATMENT MODALITIES

Target Background & Scientific Rationale
Preclinical Proof-of-Concept of Anti-CD123 Immunotherapeutics
Clinical Experience with CD123-Targeted Treatment Modalities
Target and Treatment Modality Safety Concerns of anti-CD123 Immunotherapeutics
Competitive Landscape
Profiles of Anti-CD123 Immunotherapeutics:
  Immunotoxins
  Naked Antibody
  Fc-Engineered Antibodies
  Antibody-Drug Conjugates
  T-Cell Redirecting Bispecific Antibodies
  Anti-CD123 CAR T-Cells
Company Profiles
References
ADDENDUM: Competitor Analysis of CD123-Targeted Immunotherapeutics

REPORT 3:

CD22: A SUITABLE ANTIGEN FOR TARGETED PAYLOAD DELIVERY BY IMMUNOTHERAPEUTICS

Target Background & Scientific Rationale
Clinical Proof-of-Concept of CD22-Targeted Immunotherapeutics
Competitive Landscape
Profiles of Anti-CD22 Immunotherapeutics
  Naked antibodies;
  Radioimmunotherapy (RIT);
  Immunotoxins (IT);
  Antibody-Dug Conjugates (ADC); and
  Chimeric Antigen Receptor (CAR) T-Cells.
Profiles of Companies with CD22-Targeted Immunotherapeutics
References
ADDENDUM: Competitor Analysis of of CD22-Targeted Immunotherapeutics